Matthew A. Lunning
About
Matthew A. Lunning is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics.
According to data from OpenAlex, Matthew A. Lunning has authored 163 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 85 papers in Pathology and Forensic Medicine and 49 papers in Genetics. Recurrent topics in Matthew A. Lunning's work include Lymphoma Diagnosis and Treatment (85 papers), CAR-T cell therapy research (62 papers) and Chronic Lymphocytic Leukemia Research (45 papers). Matthew A. Lunning is often cited by papers focused on Lymphoma Diagnosis and Treatment (85 papers), CAR-T cell therapy research (62 papers) and Chronic Lymphocytic Leukemia Research (45 papers). Matthew A. Lunning collaborates with scholars based in United States, Switzerland and Canada. Matthew A. Lunning's co-authors include Jamés O. Armitage, Randy D. Gascoyne, Franco Cavalli, Julie M. Vose, Steven M. Horwitz, Sarah A. Holstein, Jeremy S. Abramson, Alison J. Moskowitz, Tanya Siddiqi and Jon Arnason and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Matthew A. Lunning
155 papers receiving 3.3k citations
Hit Papers
Peers
Matthew A. Lunning
Sunita D. Nasta United States
Leslie Popplewell United States
Julio C. Chávez United States
Emmanuel Bachy France
Kirit M. Ardeshna United Kingdom
Javier Briones Spain
Craig S. Sauter United States
Mark Hertzberg Australia
Sindhu Cherian United States
Daobin Zhou China
Citations per year, relative to Matthew A. Lunning Matthew A. Lunning (= 1×)
peers
Sunita D. Nasta
Countries citing papers authored by Matthew A. Lunning
Since
Specialization
Citations
This map shows the geographic impact of Matthew A. Lunning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Lunning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Lunning more than expected).
Fields of papers citing papers by Matthew A. Lunning
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Matthew A. Lunning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Lunning. The network helps show where Matthew A. Lunning may publish in the future.
Co-authorship network of co-authors of Matthew A. Lunning
This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Lunning. A scholar is included among the top collaborators of Matthew A. Lunning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Lunning. Matthew A. Lunning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kamdar, Manali, Sairah Ahmed, Jeremy S. Abramson, et al.. (2025). CT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience. Clinical Lymphoma Myeloma & Leukemia. 25. S1010–S1011.
2.
Hunter, Bradley D., Matthew A. Lunning, Sairah Ahmed, et al.. (2025). CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplantation and Cellular Therapy. 32(2). 171.e1–171.e12.
3.
Ellithi, Moataz, Magdi Elsallab, Matthew A. Lunning, et al.. (2024). Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data. Transplantation and Cellular Therapy. 31(2). 71.e1–71.e14.
4.
Rana, Sandeep, Sarbjit Singh, Jayapal Reddy Mallareddy, et al.. (2024). Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. Cancer Research Communications. 4(5). 1328–1343.
5.
Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465.
6.
Stuver, Robert, Steven M. Horwitz, Ranjana H. Advani, et al.. (2023). Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma. British Journal of Haematology. 202(3). 525–529.
7.
High, Robin, Matthew A. Lunning, Tanya M. Wildes, et al.. (2023). Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation. Blood. 142(Supplement 1). 4966–4966.
8.
Tun, Han W., Allison Rosenthal, Matthew A. Lunning, et al.. (2023). Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies. Blood. 142(Supplement 1). 4497–4497.
9.
Green, Jesse, Aesha Vakil, Vasily V. Vagin, et al.. (2023). Feasibility of Extracorporeal Delivery of Fusosomes to Generate CAR T Cells In Vivo. Blood. 142(Supplement 1). 3631–3631.
10.
Alderuccio, Juan Pablo, Weiyun Z. Ai, John Radford, et al.. (2022). Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Advances. 6(16). 4736–4739.
11.
Solomon, Scott R., Amitkumar Mehta, Jeremy S. Abramson, et al.. (2021). Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product. Transplantation and Cellular Therapy. 27(3). S207–S208.
12.
Schmit-Pokorny, Kim, Deborah A. Swanson, Valerie Shostrom, et al.. (2021). Assessment of Time to CAR-T Cell Therapy and Patients’ Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Based on Insurance Status (Public Versus Private) and Distance Traveled to Treatment Center. Transplantation and Cellular Therapy. 27(3). S302–S303.
13.
Lunning, Matthew A., Julie M. Vose, Loretta J. Nastoupil, et al.. (2019). Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 134(21). 1811–1820.
14.
Zhang, Xuan, Chengfeng Bi, Weiwei Zhang, et al.. (2019). Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. Leukemia. 34(1). 138–150.
15.
Abramson, Jeremy S., Maria Lia Palomba, Leo I. Gordon, et al.. (2019). Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood. 134(Supplement_1). 241–241.
16.
Maloney, David G., Jeremy S. Abramson, Maria Lia Palomba, et al.. (2017). Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration. Blood. 130. 1552–1552.
17.
Chari, Ajai, Saulius Girnius, Saurabh Chhabra, et al.. (2017). Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 130. 3111–3111.
18.
Siddiqi, Tanya, Jeremy S. Abramson, D. Li, et al.. (2017). Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017. Blood. 130. 193–193.
19.
Gundabolu, Krishna, Vijaya Raj Bhatt, Matthew A. Lunning, & Muhamed Baljević. (2017). Efficacy of Direct Oral Anticoagulants (DOAC) in Patients with Antiphospholipid Antibody Syndrome (APS). Blood. 130. 4917–4917.
20.
Moskowitz, Alison J., Matthew A. Lunning, & Steven M. Horwitz. (2014). How I treat the peripheral T-cell lymphomas. Blood. 123(17). 2636–2644.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sunita D. Nasta Breakdown of academic impact, for papers by Leslie Popplewell Breakdown of academic impact, for papers by Julio C. Chávez Breakdown of academic impact, for papers by Emmanuel Bachy Breakdown of academic impact, for papers by Kirit M. Ardeshna Breakdown of academic impact, for papers by Javier Briones Breakdown of academic impact, for papers by Craig S. Sauter Breakdown of academic impact, for papers by Mark Hertzberg Breakdown of academic impact, for papers by Sindhu Cherian Breakdown of academic impact, for papers by Daobin Zhou